Activity of Oritavancin against Gram-Positive Pathogens Causing Bloodstream Infections in the United States over 10 Years: Focus on Drug-Resistant Enterococcal Subsets (2010–2019) | Zendy

Cecília G Carvalhaes | Zendy; Hélio S. Sader | Zendy; Jennifer M Streit | Zendy; Mariana Castanheira | Zendy; Rodrigo E. Mendes | Zendy

Open Access

Activity of Oritavancin against Gram-Positive Pathogens Causing Bloodstream Infections in the United States over 10 Years: Focus on Drug-Resistant Enterococcal Subsets (2010–2019)

Author(s) -

Cecília G Carvalhaes,

Hélio S. Sader,

Jennifer M Streit,

Mariana Castanheira,

Rodrigo E. Mendes

Publication year - 2021

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01667-21

Subject(s) - daptomycin , linezolid , enterococcus , enterococcus faecium , staphylococcus aureus , microbiology and biotechnology , methicillin resistant staphylococcus aureus , vancomycin , vancomycin resistant enterococcus , antibiotics , drug resistance , medicine , biology , bacteria , genetics

Oritavancin displayed potent and stable activity (MIC90 range of 0.06 to 0.5 mg/L) over a 10-year period (2010 to 2019) against Gram-positive pathogens that cause bloodstream infections (BSI), including methicillin-resistantStaphylococcus aureus (MRSA) and resistant subsets ofEnterococcus spp. Daptomycin and linezolid were also active against methicillin-resistantS. aureus and vancomycin-resistantEnterococcus (VRE). Only oritavancin and linezolid remained active againstEnterococcus faecium isolates displaying an elevated daptomycin MIC (i.e., 2 to 4 mg/L).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research